It looks like you're offline.
Open Library logo
additional options menu

MARC Record from marc_columbia

Record ID marc_columbia/Columbia-extract-20221130-011.mrc:17243592:4475
Source marc_columbia
Download Link /show-records/marc_columbia/Columbia-extract-20221130-011.mrc:17243592:4475?format=raw

LEADER: 04475cam a22004094a 4500
001 5017834
005 20221109205833.0
008 040614t20052005njua b 001 0 eng
010 $a 2004014055
020 $a158829515X (alk. paper)
035 $a(OCoLC)ocm55729829
035 $a(NNC)5017834
035 $a5017834
040 $aDLC$cDLC$dC#P$dNNC-M$dOrLoB-B
042 $apcc
050 00 $aRC677$b.C36 2005
082 00 $a616.1/07$222
245 00 $aCardiac safety of noncardiac drugs :$bpractical guidelines for clinical research and drug development /$cedited by Joel Morganroth, Ihor Gussak.
260 $aTotowa, N.J. :$bHumana Press,$c[2005], ©2005.
300 $axii, 361 pages :$billustrations (some color) ;$c26 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references and index.
505 00 $gCh. 1.$tCardiac safety of noncardiac drugs : historical recollections /$rRaymond John Lipicky -- $gCh. 2.$tMolecular physiology of ion channels that control cardiac repolarization /$rJeanne M. Nerbonne and Robert S. Kass -- $gCh. 3.$tCellular, molecular, and pharmacologic mechanisms underlying drug-induced cardiac arrhythmogenesis /$rCharles Antzelevitch -- $gCh. 4.$thERG assay, QT liability, and sudden cardiac death /$rArthur M. Brown -- $gCh. 5.$tPharmacogenomics in drug development : when and how to apply /$rRichard Judson and Arthur J. Moss -- $gCh. 6.$tAssessment of ventricular repolarization from body-surface ECGs in humans /$rJean-Philippe Couderc and Wojciech Zareba -- $gCh. 7.$tECG acquisition and signal processing : 12-lead ECG acquisition /$rJustin L. Mortara -- $gCh. 8.$tDigital 12-lead Holter vs standard resting supine electrocardiogram for the assessment of drug-induced QTc prolongation : assessment by different recording and measurement methods /$rNenad Sarapu -- $gCh. 9.$tHolter monitoring for QT : the RR bin method in depth /$rFabio Badilini and Pierre Maison-Blanche -- $gCh. 10.$tFundamentals of ECG interpretation in clinical research and cardiac safety assessment /$rIhor Gussak, Robert Kleiman and Jeffrey S. Litwin -- $gCh. 11.$tDesign and conduct of the thorough phase I ECG trial for new bioactive drugs /$rJoel Morganroth -- $gCh. 12.$tUse of ECGs in support of cardiac safety in phase II and III clinical trials /$rMartin P. Bedigian -- $gCh. 13.$tCardiac arrhythmia assessment in phase IV clinical studies /$rGerald A. Faich and Annette Stemhagen -- $gCh. 14.$tStatistical analysis plans for ECG data : controlling the intrinsic and extrinsic variability in QT data /$rAlan S. Hollister and Timothy H. Montague -- $gCh. 15.$tInterpretation of clinical ECG data : understanding the risk from non-antiarrhythmic drugs /$rRashmi R. Shah -- $gCh. 16.$tThe FDA's digital ECG initiative and its impact on clinical trials /$rBarry D. Brown -- $gCh. 17.$tQuality control and quality assurance for core ECG laboratories /$rAmy M. Annand-Furlong -- $gCh. 18.$tECG digital communities and electronic reporting of cardiac safety data : new technologies for reporting digital ECG data in clinical research settings /$rScott Grisanti and Robert Brown.
520 1 $a"Authoritative and up-to-date, Cardiac Safety of Noncardiac Drugs: Practical Guidelines for Clinical Research and Drug Development offers clinical researchers in industry and academia expert practical advice on establishing their product's cardiac safety, predicting regulatory actions, and getting it successfully to market."--BOOK JACKET.
650 0 $aCardiovascular toxicology.$0http://id.loc.gov/authorities/subjects/sh90000864
650 0 $aHeart$xEffect of drugs on.$0http://id.loc.gov/authorities/subjects/sh85059673
650 0 $aDrugs$xSide effects$xTesting.
650 0 $aElectrocardiography.$0http://id.loc.gov/authorities/subjects/sh85042098
650 12 $aCardiovascular Diseases$xchemically induced.$0https://id.nlm.nih.gov/mesh/D002318Q000139
650 12 $aPharmaceutical Preparations.$0https://id.nlm.nih.gov/mesh/D004364
650 12 $aElectrocardiography.$0https://id.nlm.nih.gov/mesh/D004562
650 22 $aCardiovascular System$xdrug effects.$0https://id.nlm.nih.gov/mesh/D002319Q000187
700 1 $aMorganroth, Joel.$0http://id.loc.gov/authorities/names/n82017045
700 1 $aGussak, Ihor.$0http://id.loc.gov/authorities/names/n2002135994
856 41 $3Table of contents$uhttp://www.loc.gov/catdir/toc/ecip0419/2004014055.html
852 00 $boff,hsl$hRC677$i.C36 2005